META 1i
Alternative Names: META-01; META-1iLatest Information Update: 19 Dec 2023
Price :
$50 *
At a glance
- Originator META Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Metabolic disorders
Most Recent Events
- 18 Dec 2023 Early research in Metabolic disorders in China (unspecified route) prior to December 2023 (META Pharmaceuticals pipeline, December 2023)
- 30 Jun 2023 META Pharmaceuticals plans to file a clinical trial application with the regulatory body in China and USA in 2024 (META Pharmaceuticals website, June 2023)
- 19 Jun 2023 Early research in Autoimmune disorders in China (unspecified route) prior to June 2023 (META Pharmaceuticals pipeline, June 2023)